Table 2.

Radiological response to treatment

	After induction (n=31)	20th cCRT (n=30)	1 month post-cCRT (n=30)
Overall tumor site
CR	8 (25.8)	24 (80.0)	28 (93.3)
PR	19 (61.3)	6 (20.0)	2 (6.7)
Reduction of ≥70% in tumor size	14 (45.2)	3 (10.0)	0
Reduction of ≥30% to <70% in tumor size	5 (16.1)	3 (10.0)	2 (6.7)
SD	4 (12.9)	0	0
PD	0	0	0
ORR	27 (87.1; 70.2 to 96.4)	30 (100.0; 88.8 to 100.0)	30 (100.0; 88.8 to 100.0)
DCR	31 (100.0; 88.4 to 100.0)	30 (100.0; 88.8 to 100.0)	30 (100.0; 88.8 to 100.0)
Response at primary sites
CR	22 (71.0)	27 (90.0)	29 (96.7)
PR	7 (22.6)	3 (10.0)	1 (3.3)
Reduction of ≥70% in tumor size	3 (9.7)	1 (3.3)	0
Reduction of ≥30% to <70% in tumor size	4 (12.9)	2 (6.7)	1 (3.3)
SD	2 (6.5)	0	0
PD	0	0	0
Response at lymph nodes
CR	14 (45.2)	25 (83.3)	29 (96.7)
PR	13 (41.9)	5 (16.7)	1 (3.3)
Reduction of ≥70% in tumor size	11 (35.5)	2 (6.7)	0
Reduction of ≥30% to <70% in tumor size	2 (6.5)	3 (10.0)	1 (3.3)
SD	4 (12.9)	0	0
PD	0	0	0

Data are n (%) or n (%, 95% CI). Efficacy was analyzed in treated patients who had baseline and post-baseline imaging assessment after induction chemoimmunotherapy, after 20 fractions of radiotherapy, and 1 month after cCRT.

cCRT, concurrent chemoradiotherapy; CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, disease progression; PR, partial response; SD, stable disease; 20th cCRT, 20 fractions of radiotherapy.